{"id":701705,"date":"2022-10-27T08:00:38","date_gmt":"2022-10-27T12:00:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/"},"modified":"2022-10-27T08:00:38","modified_gmt":"2022-10-27T12:00:38","slug":"caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/","title":{"rendered":"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System"},"content":{"rendered":"

<\/p>\n

CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System<\/b><\/p>\n

BRISBANE, Calif.–(BUSINESS WIRE<\/a>)–
\nCareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1<\/sup> for the iBox\u00ae Scoring System as a secondary endpoint in kidney transplant clinical trials.\n<\/p>\n

\n\u201cCareDx congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System. We applaud their pioneering ingenuity in customizing the iBox risk prediction scoring system for this application which is poised to have a significant impact on transplant patient lives,\u201d said Reg Seeto, CEO and President of CareDx. \u201cWe are proud to be long-standing collaborators with the incredible teams at the Transplant Therapeutics Consortium and the Paris Transplant Group and look forward to working together to drive the next wave of transplant innovation.\u201d\n<\/p>\n

\nThe iBox Scoring System is a composite biomarker that utilizes multiple clinically relevant patient features to fully reflect the heterogeneity of graft failure, including measures of renal function (eGFR and proteinuria) and immunologic response to the graft (donor-specific antibody), and assessment of allograft health through histopathology (Banff lesion scores).2 <\/sup>For more details, go here<\/a>.\n<\/p>\n

About CareDx \u2013 The Transplant Company<\/b><\/p>\n

\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com<\/b><\/a>.\n<\/p>\n

Forward Looking Statements<\/b><\/p>\n

\nThis press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with iBox Scoring System, the receipt of EMA draft qualification by C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group (\u201cReceipt of Qualification\u201d), and CareDx\u2019s collaborations with C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group (the \u201cCollaborations\u201d). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the ibox Scoring System and the Collaborations; risks that C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group do not realize the expected benefits of the iBox Scoring System, the Receipt of Qualification, and the Collaborations; general economic and market factors; and other risks discussed in CareDx\u2019s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx\u2019s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx\u2019s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.\n<\/p>\n

References<\/b><\/p>\n

    \n
  1. \nThe draft qualification opinion is going through a public consultation stage through Nov. 17, 2022.\n<\/li>\n
  2. \nAccessed online at: https:\/\/c-path.org\/c-paths-transplant-therapeutics-consortium-receives-acceptance-of-letter-of-intent-for-ibox-scoring-system-composite-biomarker-panel-as-a-reasonably-likely-surrogate-endpoint\/<\/a>. October 18, 2022\n<\/li>\n<\/ol>\n

    \n\u00a0\n<\/p>\n

    \"\"<\/p>\n

    View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221027005370\/en\/<\/a><\/span><\/p>\n

    \nCareDx, Inc.
    \n
    Media Relations
    \n
    Anna Czene
    \n
    818-731-2203
    \n
    aczene@caredx.com<\/a><\/p>\n

    \nInvestor Relations
    \n
    Ian Cooney
    \n
    (415) 722-4563
    \n
    investor@CareDx.com<\/a><\/p>\n

    KEYWORDS:<\/b> California United States North America<\/p>\n

    INDUSTRY KEYWORDS:<\/b> Health Technology Genetics Health Surgery<\/p>\n

    MEDIA:<\/b><\/p>\n\n\n\n\n
    Logo<\/b><\/font><\/td>\n<\/tr>\n
    \"Logo\"<\/td>\n<\/tr>\n
    <\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox\u00ae Scoring System as a secondary endpoint in kidney transplant clinical trials. \u201cCareDx congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System. We applaud their pioneering ingenuity in customizing the iBox risk prediction scoring system for … <\/p>\n

    Continue reading “CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701705","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox\u00ae Scoring System as a secondary endpoint in kidney transplant clinical trials. \u201cCareDx congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System. We applaud their pioneering ingenuity in customizing the iBox risk prediction scoring system for … Continue reading "CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:00:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System\",\"datePublished\":\"2022-10-27T12:00:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/\"},\"wordCount\":678,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/\",\"name\":\"CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-10-27T12:00:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/","og_locale":"en_US","og_type":"article","og_title":"CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk","og_description":"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox\u00ae Scoring System as a secondary endpoint in kidney transplant clinical trials. \u201cCareDx congratulates C-Path\u2019s Transplant Therapeutics Consortium and the Paris Transplant Group for receiving this regulatory approval for the iBox Scoring System. We applaud their pioneering ingenuity in customizing the iBox risk prediction scoring system for … Continue reading \"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:00:38+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System","datePublished":"2022-10-27T12:00:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/"},"wordCount":678,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/","name":"CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-10-27T12:00:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221027005370r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-congratulates-c-paths-transplant-therapeutics-consortium-and-paris-transplant-group-for-receiving-ema-draft-qualification-for-ibox-scoring-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CareDx Congratulates C-Path’s Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701705"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701705\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}